Unchanged Antibiotic Susceptibility in Escherichia coli and Pseudomonas aeruginosa after Long-Term in vitro Exposure to Antineoplastic Drugs
Kvaalostad, K.M.; Gammelrud, K.W.; Brandtzæg, P.; Husby, E.A. (Oslo)

Microbiology

Guiral, E.; Bosch, J.; Vila, J.; Soto, S.M. (Barcelona)

Effects of Anidulafungin and Voriconazole, Singly and in Combination, on Cytokine/Chemokine Production by Human Monocyte-Derived Macrophages Infected with Candida glabrata or Activated by Lipopolysaccharide
Baltch, A.L.; Lawrence, D.; Ritz, W.; Andersen, N. (Albany, N.Y.); Repp, L.H. (Albany, N.Y./Cobleskill, N.Y.); Michelsen, P.B.; Carlyn, C.J.; Smith, R.P. (Albany, N.Y.)

Study of the Correlation of Impenem Resistance with Efflux Pumps AdeABC, AdeDE and AdeIJK in Clinical Isolates of Acinetobacter baumannii
Hou, P.F.; Chen, X.Y.; Yan, G.F.; Wang, Y.P.; Ying, C.M. (Shanghai)

Comparison of the Kidney Fungal Burden in Experimental Disseminated Candidiasis by Species of the Candida parapsilosis Complex Treated with Fluconazole, Amphotericin B and Caspofungin in a Temporarily Neutropenic Murine Model

Chemotherapy

Effect of Neoadjuvant Chemotherapy in Hepatic Steatosis
Jiménez, R.; Hijona, E.; Empanaran, J.; Aliattia, J.M.; Hijona, L. (San Sebastián); Macarulla, M.T.; Portillo, M.P. (Vitoria); Herreos-Villanueva, M.; Beguiristain, A.; Arenas, J.; Bujanda, L. (San Sebastián)

Short-Chain Fatty Acids Induce Apoptosis in Colon Cancer Cells Associated with Changes to Intracellular Redox State and Glucose Metabolism

Enhancement of the Antitumor Effect on Combination Therapy of an Anticancer Drug and Its Antibody against Carcinoembryonic Antigen
Shibaguchi, H.; Tsuru, H.; Kuroki, M.; Kuroki, M. (Fukuoka)

Animal Model Methodology: Immunocompetent or Leucopenic Rats, Which Is the Best? Results from a Model of Experimental Pneumonia due to Derepressed Cephalosporinase-Producing Enterobacter cloacae
Jacolot, A. (Bobigny/Poitiers); Judel, C.; Chaumais, M.-C.; Nicolas, P. (Bobigny); Marchand, S. (Poitiers); Petitjean, O. (Bobigny); Mimou, O. (Poitiers)

The Different Induction Mechanisms of Growth Arrest DNA Damage Inducible Gene 45  in Human Hepatoma Cell Lines

Tailoring Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer: A Historical Prospective Study
Zee, A.; Rued, S. (Petitac Tïkva); Braunstein, R. (Tel Aviv); Yershalim, R.; Hendor, D.; Neimann, V.; Gareuuru, N. (Petitac Tïkva); Sulkes, A.; Stummer, S.M. (Petitac Tïkva/Tel Aviv)

Chemotherapy for Inoperable Advanced or Metastatic Cholangiocarcinoma: Retrospective Analysis of 78 Cases in a Single Center over Four Years
Pracht, M.; De Roux, G.; Selupe, L.; Mesbah, H.; Manfredi, S.; Audrain, O.; Boulema, K. (Rennes); Raoul, J.-L. (Marseille); Boucher, E. (Rennes)

Sunitinib-Induced Autoimmune Thyroiditis in a Patient with Metastatic Renal Cell Carcinoma: A Case Report
Bahanc, T. (Shihii Ankaras); Sevinic, A.; Akarsu, E.; Balikan, O. (Gaziantep)
Knowing One’s Medical Fate in Advance

Challenges for Diagnosis and Treatment, Philosophy, Ethics, and Religion

Editors
Georg Pfeiderer
Manuel Battegay
Klaus Lindpaintner

Modern medicine is now in a position to make advanced prognoses that chart the entire course of illness and recovery. Paradoxically, this is coupled with a new dimension of uncertainty for the patient, i.e. coming to terms with discovering they have an increased risk of a particular disease and deciding what appropriate steps to take. In this publication, renowned experts in their fields discuss these issues. The certainty and uncertainty of one’s fate are discussed from both methodological and epistemological perspectives, using examples of diseases for which treatment and prognosis have dramatically changed. Despite profound insights into the human genome, personalized genetically tailored medicine still lies in the future. Religious, spiritual and philosophical dimensions are discussed, as are the ways in which they may help people cope with these new insights into their future, e.g. the promise of an afterlife.

This publication aims to bridge the different fields dealing with this area by addressing the challenges faced and encouraging dialogue. It will be of interest to all readers who deal with ethical problems of prognosis, particularly in medicine, as well as to theologians and sociologists.

Religious Perspectives
- Fate and Judaism – Philosophical and Clinical Aspects: Gross, T.; Steinhart, H.
- Karma, Contingency, and the Point of No Return: Predictive Medicine and Buddhist Perspectives: Sobelmann, J.

Author Index
Subject Index

Contents

Introduction: Pfeiderer, G.; Battegay, M.; Lindpaintner, K.
Medical Perspectives
- Evolving Therapy and Prognosis in HIV – How Knowing One’s Medical Fate in Advance Can Change Dramatically: Battegay, M.
- Related to Human Cognition: Is Personalization Feasible and Desirable?: Laxer, R.W.

Ethical and Juridical Perspectives
- Ethical Decision-Making on Genetic Diagnosis Facing the Challenges of Knowing One’s Medical Fate in Advance: Bircher, A.
- Predictive Medicine – Changes in Our View of Ourselves and Others: Bircher, A.
- Current Challenges for the Law: Disclosure Dilemmas in Predictive Medicine: Dene, B.S.

Adverse Cutaneous Drug Reactions

B. Belloni, Zurich
R. Breslow, Boston, Mass.
K. Brockow, Munich
M. Castells, Boston, Mass.
L.E. French, Zurich
M. Glatz, Zurich
S.M. Goldinger, Zurich
G.F.L. Hofbauer, Zurich
Y. Kano, Tokyo
K. Kerl, Zurich
Y. Mizukawa, Tokyo
W.J. Pichler, Bern
M. Pirmohamed, Liverpool
S. Rozati, Zurich
T. Shiohara, Tokyo
A. Sidoroff, Innsbruck
D. Sloane, Boston, Mass.
A. Taieb, Bordeaux
R. Takahashi, Tokyo

Preface: French, L.E.

Epidemiology of Cutaneous Adverse Drug Reactions: Mackenbach, H.
Genetics and the Potential for Predictive Tests in Adverse Drug Reactions: Rijks, C.F.
Etiology and Pathogenesis of Adverse Drug Reactions: Munnich, O.; Schnyder, B.; Pichler, W.
Diagnostic Approach to Drug Allergy: Harr, T. Diagnostisches Verfahren Indizierbar: Harr, T.
Dilemmas in Predictive Medicine: Bircher, A.

Drug-Induced Angioedema: Dörf, B.S.
Fixed Drug Eruption: The Dark Side of Activation of Interspecies CD8+ T Cells: uniquely specializing in Protective Immunity: Shisharo, T.; Mizutani, Y.
Drug-Induced Hypersensitivity Syndrome: Recent Advances in the Diagnosis, Pathogenesis and Management: Shisharo, T.; Kano, Y.; Takahashi, R.; Ishida, T.; Mizutani, Y.

Diseases:
- Acute Generalized Exanthematous Pustulosis: Dörr, B.S.
- Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Harr, T.; French, L.E.
- Photoxic and Phototoxic Cutaneous Drug Reactions: Dörr, B.S.; Hofbauer, G.F.L.
- Immediate and Delayed Cutaneous Reactions to Radiocontrast Media: Kucera, R.

Conclusion: Adverse Cutaneous Drug Eruptions Associated with the Use of New Oncological Drugs: Kucera, R.; Schickwitz, A.; Raehle, U.; Goldinger, S.M.; Dörr, R.

Cytogenetic Cutaneous Drug Reactions: Raehle, U.

Drug Reactions:
- Drug-Induced Anaphylaxis: Harr, T.
- Fixed Drug Eruption: The Dark Side of Activation of Interspecies CD8+ T Cells: uniquely specializing in Protective Immunity: Shisharo, T.; Mizutani, Y.

Drug-Induced Hypersensitivity Syndrome: Recent Advances in the Diagnosis, Pathogenesis and Management: Shisharo, T.; Kano, Y.; Takahashi, R.; Ishida, T.; Mizutani, Y.

Adverse Cutaneous Drug Reactions

Editor
Lars E. French

Contents

Preface: French, L.E.

Epidemiology of Cutaneous Adverse Drug Reactions: Mackenbach, H.
Genetics and the Potential for Predictive Tests in Adverse Drug Reactions: Rijks, C.F.
Etiology and Pathogenesis of Adverse Drug Reactions: Munnich, O.; Schnyder, B.; Pichler, W.
Diagnostic Approach to Drug Allergy: Harr, T.
Dilemmas in Predictive Medicine: Bircher, A.

Drug-Induced Angioedema: Dörf, B.S.
Fixed Drug Eruption: The Dark Side of Activation of Interspecies CD8+ T Cells: uniquely specializing in Protective Immunity: Shisharo, T.; Mizutani, Y.

Diseases:
- Acute Generalized Exanthematous Pustulosis: Dörr, B.S.
- Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Harr, T.; French, L.E.
- Photoxic and Phototoxic Cutaneous Drug Reactions: Dörr, B.S.; Hofbauer, G.F.L.
- Immediate and Delayed Cutaneous Reactions to Radiocontrast Media: Kucera, R.

Conclusion: Adverse Cutaneous Drug Reactions Associated with the Use of New Oncological Drugs: Kucera, R.; Schickwitz, A.; Raehle, U.; Goldinger, S.M.; Dörr, R.

Cytogenetic Cutaneous Drug Reactions: Raehle, U.

Drug Reactions:
- Drug-Induced Anaphylaxis: Harr, T.
- Fixed Drug Eruption: The Dark Side of Activation of Interspecies CD8+ T Cells: uniquely specializing in Protective Immunity: Shisharo, T.; Mizutani, Y.
Submission
Only original papers written in English are considered for publication. Manuscripts should be submitted to ‘Chemotherapy’ online. For specific instructions on how to prepare a manuscript for submission, you are encouraged to view the guidelines at www.karger.com/che, where you will also find a link to the Submission Website. Names, postal and e-mail addresses of four experts in the appropriate area of research should accompany each manuscript. Selected scientist(s) will be invited to act as referee(s). Referees suggested should not be from the same institution as the author and experts in the appropriate area of research should be encouraged to view the guidelines at www.karger.com/che.

Conditions
All manuscripts are subject to editorial review. Manuscripts are received with the explicit understanding that they are not under simultaneous consideration by any other publication. Submission of an article for publication implies the transfer of the copyright from the author to the publisher upon acceptance. Accepted papers become the permanent property of ‘Chemotherapy’ and may not be reproduced by any means, in whole or in part, without the written consent of the publisher. It is the author’s responsibility to obtain permission to reproduce illustrations, tables, etc. from other publications.

Arrangement
Lines should be numbered on the margin.

Title page: The first page of each paper should indicate the title, the authors’ names, the institute where the work was conducted, and a short title for use as running head.

Full address: The exact postal address of the corresponding author complete with postal code must be given at the bottom of the title page. Please also supply phone and fax numbers, as well as e-mail address.

Key words: Please supply 3–10 key words in English that reflect the content of the paper.

Abstract: Each paper needs an abstract of up to 150 words structured with subheadings as follows: Background, Methods, Results, Conclusion(s).

Footnotes: Avoid footnotes. When essential, they are numbered consecutively and typed at the foot of the appropriate page.

Tables and illustrations: Tables and illustrations (both numbered in Arabic numerals) should be prepared on separate sheets. Tables require a heading and figures a legend, also prepared on a separate sheet. For the reproduction of illustrations, only good drawings and original photographs can be accepted; negatives or photocopies cannot be used. Due to technical reasons, figures with a screen background should not be submitted. When possible, group several illustrations on one block for reproduction (max. size 180 × 223 mm) or provide crop marks. Electronically submitted b/w half-tone and color illustrations must have a final resolution of 300 dpi after scaling, line drawings one of 800–1200 dpi.

Color illustrations
Online edition: Color illustrations are reproduced free of charge. In the print version, the illustrations are reproduced in black and white. Please avoid referring to the colors in the text and figure legends.

Print edition: Up to 6 color illustrations per page can be integrated within the text at CHF 800.– per page. References: In the title identify references by Arabic numerals [in square brackets]. Material submitted for publication but not yet accepted should be noted as ‘unpublished data’ and not be included in the reference list. The list of references should include only those publications which are cited in the text. Do not alphabetize; number references in the order in which they are first mentioned in the text. The surnames of the authors followed by initials should be given. There should be no punctuation other than a comma to separate the authors. Preferably, please cite all authors. Abbreviate journal names according to the Index Medicus system. Also see International Committee of Medical Journal Editors: Uniform requirements for manuscripts submitted to biomedical journals (www.icmje.org).

Examples
(b) Papers published only with DOI numbers: Theoharides TC, Boucher W, Spear K: Interleukin-6 reflects disease severity and osteoporosis in mastocytosis patients. Int Arch Allergy Immunol DOI: 10.1159/000063858.

Reference Management Software: Use of EndNote is recommended for easy management and formatting of citations and reference lists.

Digital Object Identifier (DOI)
S. Karger Publishers supports DOIs as unique identifiers for articles. A DOI number will be printed on the title page of each article. DOIs can be useful in the future for identifying and citing articles published online without volume or issue information. More information can be found at www.doi.org.

Supplementary Material
Supplementary material is restricted to additional data that are not necessary for the scientific integrity and conclusions of the paper. Please note that all supplementary files will undergo editorial review and should be submitted together with the original manuscript. The Editors reserve the right to limit the scope and length of the supplementary material. Supplementary material must meet production quality standards for Web publication without the need for any modification or editing. In general, supplementary files should not exceed 10 MB in size. All figures and tables should have titles and legends and all files should be supplied separately and named clearly. Acceptable files and formats are: Word or PDF files, Excel spreadsheets (only if the data cannot be converted properly to a PDF file), and video files (.mov, .avi, .mpeg).

Author’s Choice™
Karger’s Author’s Choice™ service broadens the reach of your article and gives all users worldwide free and full access for reading, downloading and printing at www.karger.com. The option is available for a one-time fee of CHF 3000.–, which is a permissible cost in grant allocation. More information can be found at www.karger.com/authors_choice.

NIH-Funded Research
The U.S. National Institutes of Health (NIH) mandates under the NIH Public Access Policy that final, peer-reviewed manuscripts appear in its digital database within 12 months of the official publication date. As a service to authors, Karger submits the final version of your article on your behalf to PubMed Central. For those selecting our premium Author’s Choice™ service, we will send your article immediately upon publishing, accelerating the accessibility of your work without the usual embargo. More details on NIH’s Public Access Policy is available at http://publicaccess.nih.gov/FAQ.htm#1.

Self-Archiving
Karger permits authors to archive their pre-prints (i.e. pre-refereeing) or post-prints (i.e. final draft post-refereeing) on their personal or institution’s servers, provided the following conditions are met: Articles may not be used for commercial purposes, must be linked to the publisher’s version, and must acknowledge the publisher’s copyright. Authors selecting Karger’s Author’s Choice™ feature, however, are also permitted to archive the final, published version of their article, which includes copyediting and design improvements as well as citation links.

Page Charges
There is no page charge for papers of 4 or fewer printed pages (including tables, illustrations and references). Each additional complete or partial page is charged to the author at CHF 130.–. The allotted size of a paper is 5 printed pages (including tables, illustrations and references).

Proofs
Unless indicated otherwise, proofs are sent to the corresponding author and should be returned with the least possible delay. Alterations made in proofs, other than the correction of printer’s errors, are charged to the author.

Reprints
Orders and a price list are sent with the proofs. Orders submitted after the issue is printed are subject to considerably higher prices.
Human papillomaviruses (HPV) are a heterogeneous and still growing virus family. Topical research results on the replication cycle and carcinogenic mechanisms allow a better understanding of current prevention strategies. Written by leading experts, this volume of Monographs in Virology provides up-to-date information on the prevention of papillomavirus-induced cancers by prophylactic antiviral vaccines and early detection of precancerous lesions.

A major section covers the tremendous clinical burden due to HPV infections: genital warts and laryngeal papillomas, the most notorious cervical cancer, but also further anogenital and tonsillar cancer, the incidence of which increased steeply during the last decades. Additionally, a section on prevention addresses the subject cytology – new concepts of biomarker development, detection of HPV DNA and RNA as well as their use in primary screening for early detection of precancerous lesions. Finally the book closes with a topical discussion of the most intriguing primary prevention of HPV infection by vaccination.

As new perspectives for the prevention of HPV-related neoplasia raised great public interest, this book will be of value to clinicians and practitioners in gynecology, dermatology, urology and ENT, to pathologists, laboratory physicians, medical students, and public health authorities.

Contents

Foreword: Pfister, H.

Virology and Pathogenesis: Pfister, H.

Epidemiology of Mucosotropic Papillomaviruses: Gissmann, L.

Clinical Aspects of Low-Risk HPV Infections
  • Condylomata Acuminata: Gross, G.
  • Recurrent Respiratory Papillomatosis: Wittekindt, C.; Wagner, S.; Klussmann, J.P.

Clinical Aspects of High-Risk HPV Infections
  • Cervical Cancer and Intraepithelial Neoplasia: Schneider, A.; Köhler, C.; Chiantera, V.; Vercellino, F.
  • Cancer and Intraepithelial Neoplasia of the Vulva and Vagina: Petry, K.U.
  • Penile Cancer and Penile Intraepithelial Neoplasia: Gross, G.F.
  • Anal Cancer and Intraepithelial Neoplasia of the Vervellino: Wieland, U.; Kreuter, A.
  • Tonsillar Cancer: Klussmann, J.P.; Wagner, S.; Wittekindt, C.

Diagnosis for Early Detection
  • Cytology: Ikenberg, H.
  • Concepts of Biomarker Development: von Knebel Doeberitz, M.; Vinokurova, S.; Reuschenbach, M.
  • Detection of Human Papillomavirus DNA and RNA: Ikenberg, H.
  • Human Papillomavirus Testing in Primary Screening for Cervical Cancer: Petry, K.U.

Primary Prevention by Vaccination: Kaufmann, A.M.; Gissmann, L.

Author Index

Subject Index
HPV-Related Neoplasia
Prophylaxis and Early Detection of

Series Editor: Doerr, H.W. (Frankfurt a.M.)
Monographs in Virology, Vol. 28


23. Jahrestagung der Paul-Ehrlich-Gesellschaft für Chemotherapie e.V.

Symposien
• Neue Antiinfektiva und neue Erkenntnisse zu antimikrobiellen Substanzen
• Leitlinien der PEG
• Inhalative Antibiotikatherapie
• Prinzipien der antiinfektiven Therapie beim Intensivpatienten
• Infektionen in der Primärversorgung

Die CME Akkreditierung wurde beantragt.

Kongresssekretariat
Paul-Ehrlich-Gesellschaft für Chemotherapie e.V.
Geschäftsstelle
Campus Hochschule Bonn-Rhein-Sieg
Von-Liebig-Straße 20
D–53359 Rheinbach (Germany)
Tel. +49 (0) 2226 908 916
Fax +49 (0) 2226 908 918
E-Mail geschaeftsstelle@p-e-g.org

www.p-e-g.org/jahrestagung_2012

DEUTSCHES HYGIENE-MUSEUM DRESDEN
Abstracts for 13th Asia-Pacific Congress of Clinical Microbiology and Infection (13th APCCMI) are highly welcomed!

CALL FOR ABSTRACTS

Collaboration in the Management of Infections: Right Ideas, Right Actions, and Right Now

www.apccmi2012.org

Submission Deadline: May 31

Young Investigator Award

Apply online to win A TICKET & at most 4-nights STAY!

13th APCCMI Congress Secretariat: Ms. Rita Yu
Tel: +886-2-8502-7087 ext. 25 / Email: service@apccmi2012.org
Contents

See the journal website for contents
Knowing One’s Medical Fate in Advance
Challenges for Diagnosis and Treatment, Philosophy, Ethics and Religion

Editors
Georg Pfleiderer
Manuel Battegay
Klaus Lindpaintner

Modern medicine is now in a position to make advanced prognoses that chart the entire course of illness and recovery. Paradoxically, this is coupled with a new dimension of uncertainty for the patient, i.e., coming to terms with discovering they have an increased risk of a particular disease and deciding what appropriate steps to take. In this publication, renowned experts in their fields discuss these issues. The certainty and uncertainty of one’s fate are discussed from both methodological and epidemiological perspectives, using examples of diseases for which treatment and prognosis have dramatically changed. Despite profound insights into the human genome, personalized genetically tailored medicine still lies in the future. Religious, spiritual and philosophical dimensions are discussed, as are the ways in which they may help people cope with these new insights into their future, e.g., the promise of an afterlife.

This publication aims to bridge the different fields dealing with this area by addressing the challenges faced and encouraging dialogue. It will be of interest to all readers who deal with ethical problems of prognosis, particularly in medicine, as well as to theologians and sociologists.

Contents
Introduction: Pfleiderer, G.; Battegay, M.; Lindpaintner, K.

Medical Perspectives
- Evolving Therapy and Prognosis in NHL: How Knowing One’s Medical Fate in Advance Can Change Dramatically: Battegay, M.
- Related to Human Cognition: Is Personalization Feasible and Desirable?: Pfleiderer, G.

Ethical and Juridical Perspectives
- Ethical Decision-Making on Genetic Diagnosis Facing the Challenges of Knowing One’s Medical Fate in Advance: Dörr, B.S.
- Predictive Medicine – Changes in Our View of Ourselves and Others: Brosch, G.
- Current Challenges for the Law: Disclosure Dilemmas in Predictive Medicine: Dörr, B.S.

Religious Perspectives
- Fate and Judaism – Philosophical and Clinical Aspects: Gesundheit, B.
- Karma, Contingency, and the ‘Point of No Return’: Predictive Medicine and Buddhist Perspectives: Schleier, J.

Author Index
Subject Index

Adverse Cutaneous Drug Eruptions

Editor
Lars E. French

The skin is one of the most frequently involved organs in adverse drug reactions. Occurring with an incidence of 1–5% for certain types of drugs, cutaneous drug eruptions are mostly benign in nature, and comprise the most popular type of eruptions and urticaria. However, about one third of them require hospital treatment, leading to a considerable burden for the health care system. In this book, a selected group of experts provides an up-to-date, condensed and clinically relevant overview of the field of cutaneous drug eruptions, ranging from epidemiology and genetic predisposition to available therapeutic measures, including rapid drug desensitization. Reflecting the great progress made in recent years in this field, this publication will be a useful tool for a better understanding, diagnosis and management of cutaneous drug eruptions, not only for general physicians, dermatologists and clinical allergologists, but also for nurses and scientists.

Contents
Preface: French, L.E.

- Epidemiology of Cutaneous Adverse Drug Reactions: Mockenhaupt, H.
- Genetics and the Potential for Predictive Tests in Adverse Drug Reactions: Papassotiropoulos, A.
- Etiology and Pathogenesis of Adverse Drug Reactions: Hausmann, M.; Schneider, B.; Fischer, W.
- Diagnostic Approach to Drug Allergy: Herr, T.
- Histological Patterns Indicative of Distinct Adverse Drug Reactions: Kerk, K.
- Uncomplicated Drug-Induced Disseminated Exanthemas: Bröcker, E.T.
- Drug-Induced Angioedema: Lech, M.
- Fixed Drug Eruption: The Dark Side of Activation of Interspecies CD8+ T Cells: A Unique Specialized to Mediate Protective Immunity: Shishava, T.; Mizutani, Y.
- Drug-Induced Hypersensitivity Syndrome: Recent Advances in the Diagnosis, Pathogenesis and Management: Shishava, T.; Arta, Y.; Takahashi, R.; Ishida, T.; Mizutani, Y.

Author Index
Subject Index

KARGER
www.karger.com/molar-date

Orders may be placed with any bookseller, subscription agency, directly with the publisher or through a Karger distributor.

118 Unchanged Antibiotic Susceptibility in *Escherichia coli* and *Pseudomonas aeruginosa* after Long-Term in vitro Exposure to Antineoplastic Drugs
Kvikkestad, K.M.; Gammelrud, K.W.; Brandtzæg, P.; Høiby, E.A. (Oslo)

123 Antimicrobial Resistance of *Escherichia coli* Strains Causing Neonatal Sepsis between 1998 and 2008
Guiral, E.; Bosch, J.; Vila, J.; Soto, S.M. (Barcelona)

146 Effects of Anidulafungin and Voriconazole, Singly and in Combination, on Cytokine/Chemokine Production by Human Monocyte-Derived Macrophages Infected with *Candida glabrata* or Activated by Lipopolysaccharide
Baltch, A.L.; Lawrence, D.; Ritz, W.; Andersen, N. (Albany, N.Y.); Bopp, L.H. (Albany, N.Y./Cobleskill, N.Y.); Michelsen, P.B.; Carlyn, C.J.; Smith, R.P. (Albany, N.Y.)

152 Study of the Correlation of Imipenem Resistance with Efflux Pumps AdeABC, AdeDE and AdeF in Clinical Isolates of *Acinetobacter baumannii*
Hou, P.F.; Chen, X.Y.; Yan, G.F.; Wang, Y.P.; Ying, C.M. (Shanghai)

159 Comparison of the Kidney Fungal Burden in Experimental Disseminated Candidiasis by Species of the *Candida parapsilosis* Complex Treated with Fluconazole, Amphotericin B and Caspofungin in a Temporarily Neutropenic Murine Model

165 The Different Induction Mechanisms of Growth Arrest DNA Damage Inducible Gene 45 in Human Hepatoma Cell Lines

Clinical Studies

95 Tailoring Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer: A Historical Prospective Study
Zer, A.; Rizel, S. (Petach Tikva); Le Roux, G.; (Tel Aviv); Yershalmi, R.; Hendler, D.; Neimann, V.; Costescu, N. (Petach Tikva); Sulkes, A.; Stamm, S.M. (Petach Tikva/Tel Aviv)

134 Chemotherapy for Inoperable Advanced or Metastatic Cholangiocarcinoma: Retrospective Analysis of 78 Cases in a Single Center over Four Years
Pracht, M.; Le Roux, G.; Sulkes, A.; Mesbah, H.; Manfredi, S.; Audrain, O.; Boujelma, K. (Rennes); Raoul, J.-L. (Marseille); Boucher, E. (Rennes)

142 Sunitinib-Induced Autoimmune Thyroiditis in a Patient with Metastatic Renal Cell Carcinoma: A Case Report
Babacan, T. (Sıhhiye Ankara); Sevinc, A.; Akarsu, E.; Balakan, O. (Gaziantep)

110 Enhancement of the Antitumor Effect on Combination Therapy of an Anticancer Drug and Its Antibody against Carcinoembryonic Antigen
Shibaguchi, H.; Tsuji, H.; Kuroki, M.; Kuroki, M. (Fukusuka)

129 Animal Model Methodology: Immunocompetent or Leucopenic Rats, Which Is the Best? Results from a Model of Experimental Pneumonia due to Derepressed Cephalosporinase-Producing Enterobacter cloacae
Jaclot, J. (Bougny/Poitiers); Jafel, C.; Chaum, M.-C.; Louachali, K.; Nicolau, P. (Bougny); Marchand, S. (Poitiers); Petitjean, O. (Bougny); Mimou, O. (Poitiers)

102 Short-Chain Fatty Acids Induce Apoptosis in Colon Cancer Cells Associated with Changes to Intracellular Redox State and Glucose Metabolism

89 Effect of Neoadjuvant Chemotherapy in Hepatic Steatosis
Jiménez, R.; Hijona, E.; Eumaropani, J.; Allatista, J.M.; Hijona, L. (San Sebastian); Macarraci, M.T.; Portillo, M.P. (Vitoria); Herrerera-Villanueva, M.; Beguiristain, A.; Arenas, J.; Bujanda, L. (San Sebastian)

106 Short-Chain Fatty Acids Induce Apoptosis in Colon Cancer Cells Associated with Changes to Intracellular Redox State and Glucose Metabolism

90 Sunitinib-Induced Autoimmune Thyroiditis in a Patient with Metastatic Renal Cell Carcinoma: A Case Report
Babacan, T. (Sıhhiye Ankara); Sevinc, A.; Akarsu, E.; Balakan, O. (Gaziantep)